Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response

about

Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q50098437-374370B6-E474-45C3-A1B5-2650A13BCDD5 Q55283747-D4DBD55C-CEAE-4092-A7F5-EBBBC4C834FA

P2860

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response

Item

http://www.wikidata.org/entity/Q38896113

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Development of Novel Anti-Cd20 ...... Improve Immunotherapy Response

@en

type

Item

label

Development of Novel Anti-Cd20 ...... Improve Immunotherapy Response

@en

prefLabel

Development of Novel Anti-Cd20 ...... Improve Immunotherapy Response

@en

P1476

Development of Novel Anti-Cd20 ...... Improve Immunotherapy Response

@en

P2093

Alexandru Almasan

http://www.w3.org/2001/XMLSchema#string

Damodar Gupta

http://www.w3.org/2001/XMLSchema#string

Vijay Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis

Novel CD20 monoclonal antibodies for lymphoma therapy

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

P304

347-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4172/1948-5956.1000373

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27413424

http://www.w3.org/2001/XMLSchema#string

P932

4939752

http://www.w3.org/2001/XMLSchema#string

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response

about

P2860

P2860

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932